MATINAS BIOPHARMA HOLDINGS, INC. Fair Value, Net Asset (Liability)
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) had Fair Value, Net Asset (Liability) of $27.77 million as of 2019-12-31, per its 10-K filed 2021-03-29.
Discontinued › Notes › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
us-gaap:FairValueNetAssetLiability · last filed 2021-03-29
- 2019-12-31: Fair Value, Net Asset (Liability) $27.77M.
| Period end | Fair Value, Net Asset (Liability) |
|---|---|
| 2019-12-31 | $27.77M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |